Zhejiang Kanglaite to Start US Phase III Trial of TCM Cancer Drug

Zhejiang Kanglaite Group will start a large US Phase III trial of its lead drug, Kanglaite, a TCM-derived medication, in patients with pancreatic cancer. The company says Kanglaite Injection is a novel dual-function drug that kills cancer cells while strengthening immune function. Its active ingredient is derived from coix, a grass related to rice and maize. The trial of the drug, which has been approved in China since 1995, will be conducted by Kanglaite's US subsidiary. Share this with colleagues: // //